- Home
- HL vs ACAD Comparison
HL vs ACAD Comparison
Compare HL & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HL
- ACAD
- Stock Information
- Founded
- HL 1891
- ACAD 1993
- Country
- HL United States
- ACAD United States
- Employees
- HL N/A
- ACAD N/A
- Industry
- HL Precious Metals
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- HL Basic Materials
- ACAD Health Care
- Exchange
- HL Nasdaq
- ACAD Nasdaq
- Market Cap
- HL 4.1B
- ACAD 2.9B
- IPO Year
- HL N/A
- ACAD 2004
- Fundamental
- Price
- HL $5.78
- ACAD $16.78
- Analyst Decision
- HL Strong Buy
- ACAD Buy
- Analyst Count
- HL 3
- ACAD 19
- Target Price
- HL $8.50
- ACAD $25.33
- AVG Volume (30 Days)
- HL 23.8M
- ACAD 1.8M
- Earning Date
- HL 05-07-2025
- ACAD 05-07-2025
- Dividend Yield
- HL 0.65%
- ACAD N/A
- EPS Growth
- HL N/A
- ACAD N/A
- EPS
- HL 0.06
- ACAD 1.36
- Revenue
- HL $929,925,000.00
- ACAD $957,797,000.00
- Revenue This Year
- HL $9.04
- ACAD $13.07
- Revenue Next Year
- HL $4.04
- ACAD $9.97
- P/E Ratio
- HL $101.63
- ACAD $12.26
- Revenue Growth
- HL 29.12
- ACAD 31.85
- 52 Week Low
- HL $4.04
- ACAD $14.15
- 52 Week High
- HL $7.68
- ACAD $20.68
- Technical
- Relative Strength Index (RSI)
- HL 57.46
- ACAD 33.12
- Support Level
- HL $5.08
- ACAD $17.85
- Resistance Level
- HL $5.61
- ACAD $19.69
- Average True Range (ATR)
- HL 0.27
- ACAD 0.75
- MACD
- HL 0.05
- ACAD -0.30
- Stochastic Oscillator
- HL 90.10
- ACAD 4.71
About HL Hecla Mining Company
Hecla Mining Co produces and explores silver, gold, zinc and other metals. The operating business segments are Greens Creek, Lucky Friday, Keno Hill, Casa Berardi, and Nevada Operations. It generates maximum revenue from the Greens Creek segment. Geographically, It operates in Canada , United States and Mexico and it derives a majority of its revenue from United States.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.